Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
GlobalData analysis suggests that China will lead with the highest number of prevalent cases of Alzheimer’s disease in 2033.
A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.
Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.